<DOC>
	<DOCNO>NCT01730664</DOCNO>
	<brief_summary>Rationale : Treatment multidrug extensively drug resistant tuberculosis ( MDR/XDR-TB ) real challenge failure response treatment serious side-effects frequently encounter . New , effective drug less side effect therefore urgently need solve problem . Although several new drug TB pipeline , physician currently limit treatment option treatment complicate MDR/XDR-TB case . Therefore , drug develop label infectious disease evaluate TB . Objective : The main objective prospective clinical trial evaluate pharmacokinetics standard dose ( 2000mg ) ertapenem TB patient . This clinical trial provide important information PK ertapenem TB patient future study . Data use limited sampling strategy ertapenem base pharmacokinetic population model construct full PK curve patient . Study design : A prospective pharmacokinetic study . Study population : 12 TB patient . Intervention : Single dose 2000mg 30 minute intravenous infusion . Main study parameters/endpoints : The pharmacokinetic parameter ( Vd , Cl , AUC , etc ) ertapenem primary endpoint study . The T &gt; MIC AUC0-24h/Minimal inhibitory concentration ( MIC ) ratio likely best predictive parameter efficacy ertapenem treatment calculate range M tuberculosis isolates .</brief_summary>
	<brief_title>PK/PD Ertapenem In Patients With TB</brief_title>
	<detailed_description />
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Patients TB , Mycobacterium tuberculosis ( M. africanum ) culture / molecular test Adults : 18 year 64 year age Contraindications ertapenem : There adverse effect ertapenem . The absolute contra indication previous anaphylactic reaction ertapenem Î²lactam antibiotic . Renal Insufficiency , define eGFR 30ml/min Pregnancy HIV Body weight &lt; 40 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ertapenem</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>